524 related articles for article (PubMed ID: 33432241)
1. Reverse engineering Lewy bodies: how far have we come and how far can we go?
Fares MB; Jagannath S; Lashuel HA
Nat Rev Neurosci; 2021 Feb; 22(2):111-131. PubMed ID: 33432241
[TBL] [Abstract][Full Text] [Related]
2. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration.
Mahul-Mellier AL; Burtscher J; Maharjan N; Weerens L; Croisier M; Kuttler F; Leleu M; Knott GW; Lashuel HA
Proc Natl Acad Sci U S A; 2020 Mar; 117(9):4971-4982. PubMed ID: 32075919
[TBL] [Abstract][Full Text] [Related]
3. Do Lewy bodies contain alpha-synuclein fibrils? and Does it matter? A brief history and critical analysis of recent reports.
Lashuel HA
Neurobiol Dis; 2020 Jul; 141():104876. PubMed ID: 32339655
[TBL] [Abstract][Full Text] [Related]
4. Alpha-synuclein from patient Lewy bodies exhibits distinct pathological activity that can be propagated in vitro.
Marotta NP; Ara J; Uemura N; Lougee MG; Meymand ES; Zhang B; Petersson EJ; Trojanowski JQ; Lee VM
Acta Neuropathol Commun; 2021 Nov; 9(1):188. PubMed ID: 34819159
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions.
Paleologou KE; Oueslati A; Shakked G; Rospigliosi CC; Kim HY; Lamberto GR; Fernandez CO; Schmid A; Chegini F; Gai WP; Chiappe D; Moniatte M; Schneider BL; Aebischer P; Eliezer D; Zweckstetter M; Masliah E; Lashuel HA
J Neurosci; 2010 Mar; 30(9):3184-98. PubMed ID: 20203178
[TBL] [Abstract][Full Text] [Related]
6. Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease.
Covell DJ; Robinson JL; Akhtar RS; Grossman M; Weintraub D; Bucklin HM; Pitkin RM; Riddle D; Yousef A; Trojanowski JQ; Lee VM
Neuropathol Appl Neurobiol; 2017 Dec; 43(7):604-620. PubMed ID: 28386933
[TBL] [Abstract][Full Text] [Related]
7. Neuropathology of synuclein aggregates.
Duda JE; Lee VM; Trojanowski JQ
J Neurosci Res; 2000 Jul; 61(2):121-7. PubMed ID: 10878583
[TBL] [Abstract][Full Text] [Related]
8. The role of α-synuclein in neurodegenerative diseases: from molecular pathways in disease to therapeutic approaches.
Al-Mansoori KM; Hasan MY; Al-Hayani A; El-Agnaf OM
Curr Alzheimer Res; 2013 Jul; 10(6):559-68. PubMed ID: 23899170
[TBL] [Abstract][Full Text] [Related]
9. A light-inducible protein clustering system for in vivo analysis of α-synuclein aggregation in Parkinson disease.
Bérard M; Sheta R; Malvaut S; Rodriguez-Aller R; Teixeira M; Idi W; Turmel R; Alpaugh M; Dubois M; Dahmene M; Salesse C; Lamontagne-Proulx J; St-Pierre MK; Tavassoly O; Luo W; Del Cid-Pellitero E; Qazi R; Jeong JW; Durcan TM; Vallières L; Tremblay ME; Soulet D; Lévesque M; Cicchetti F; Fon EA; Saghatelyan A; Oueslati A
PLoS Biol; 2022 Mar; 20(3):e3001578. PubMed ID: 35263320
[TBL] [Abstract][Full Text] [Related]
10. Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration.
Tsika E; Moysidou M; Guo J; Cushman M; Gannon P; Sandaltzopoulos R; Giasson BI; Krainc D; Ischiropoulos H; Mazzulli JR
J Neurosci; 2010 Mar; 30(9):3409-18. PubMed ID: 20203200
[TBL] [Abstract][Full Text] [Related]
11. E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment.
Emmer KL; Waxman EA; Covy JP; Giasson BI
J Biol Chem; 2011 Oct; 286(40):35104-18. PubMed ID: 21846727
[TBL] [Abstract][Full Text] [Related]
12. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.
Uversky VN
J Neurochem; 2007 Oct; 103(1):17-37. PubMed ID: 17623039
[TBL] [Abstract][Full Text] [Related]
13. Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions.
Popescu A; Lippa CF; Lee VM; Trojanowski JQ
Arch Neurol; 2004 Dec; 61(12):1915-9. PubMed ID: 15596612
[TBL] [Abstract][Full Text] [Related]
14. Patient-specific pluripotent stem cell-based Parkinson's disease models showing endogenous alpha-synuclein aggregation.
Oh Y
BMB Rep; 2019 Jun; 52(6):349-359. PubMed ID: 31186086
[TBL] [Abstract][Full Text] [Related]
15. Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.
Uchihara T; Giasson BI
Acta Neuropathol; 2016 Jan; 131(1):49-73. PubMed ID: 26446103
[TBL] [Abstract][Full Text] [Related]
16. α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.
Henderson MX; Trojanowski JQ; Lee VM
Neurosci Lett; 2019 Sep; 709():134316. PubMed ID: 31170426
[TBL] [Abstract][Full Text] [Related]
17. Structurally distinct α-synuclein fibrils induce robust parkinsonian pathology.
Hayakawa H; Nakatani R; Ikenaka K; Aguirre C; Choong CJ; Tsuda H; Nagano S; Koike M; Ikeuchi T; Hasegawa M; Papa SM; Nagai Y; Mochizuki H; Baba K
Mov Disord; 2020 Feb; 35(2):256-267. PubMed ID: 31643109
[TBL] [Abstract][Full Text] [Related]
18. Autophagic adapter protein NBR1 is localized in Lewy bodies and glial cytoplasmic inclusions and is involved in aggregate formation in α-synucleinopathy.
Odagiri S; Tanji K; Mori F; Kakita A; Takahashi H; Wakabayashi K
Acta Neuropathol; 2012 Aug; 124(2):173-86. PubMed ID: 22484440
[TBL] [Abstract][Full Text] [Related]
19. Inoculation of α-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve.
Uemura N; Yagi H; Uemura MT; Hatanaka Y; Yamakado H; Takahashi R
Mol Neurodegener; 2018 May; 13(1):21. PubMed ID: 29751824
[TBL] [Abstract][Full Text] [Related]
20. Interaction with synphilin-1 promotes inclusion formation of alpha-synuclein: mechanistic insights and pathological implication.
Xie YY; Zhou CJ; Zhou ZR; Hong J; Che MX; Fu QS; Song AX; Lin DH; Hu HY
FASEB J; 2010 Jan; 24(1):196-205. PubMed ID: 19762560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
